Larvol Delta - Another-IL17A-molecule-Izokibep-for-PsA-Also-Bimekizumab-IL17A-and-F-Move-on-over-Ixekizumab-Secukinumab-and-Brodalumab-No-idea-what-drug-will-win-except-brodalumab-is-not-enter-psoriatic-arthritis-market

Taltz (ixekizumab) - Eli Lilly, Japan Tobacco

Bimzelx (bimekizumab) - UCB

Cosentyx (secukinumab) - Novartis

izokibep (ABY-035) - Affibody, ACELYRIN

Siliq (brodalumab) - Bausch Health, LEO Pharma, Kyowa Kirin

https://twitter.com/Janetbirdope/status/1540571340029267968

Jun 24, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next